191 related articles for article (PubMed ID: 10617686)
21. Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer.
Rizzi C; Alfano M; Bugatti A; Camozzi M; Poli G; Rusnati M
Eur J Immunol; 2004 Feb; 34(2):530-6. PubMed ID: 14768058
[TBL] [Abstract][Full Text] [Related]
22. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
Oberlin E; Amara A; Bachelerie F; Bessia C; Virelizier JL; Arenzana-Seisdedos F; Schwartz O; Heard JM; Clark-Lewis I; Legler DF; Loetscher M; Baggiolini M; Moser B
Nature; 1996 Aug; 382(6594):833-5. PubMed ID: 8752281
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
Jiang MC; Lin JK; Chen SS
Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
[TBL] [Abstract][Full Text] [Related]
24. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.
Howard OM; Oppenheim JJ; Hollingshead MG; Covey JM; Bigelow J; McCormack JJ; Buckheit RW; Clanton DJ; Turpin JA; Rice WG
J Med Chem; 1998 Jun; 41(13):2184-93. PubMed ID: 9632350
[TBL] [Abstract][Full Text] [Related]
26. Novel compounds in preclinical/early clinical development for the treatment of HIV infections.
De Clercq E
Rev Med Virol; 2000; 10(4):255-77. PubMed ID: 10891872
[TBL] [Abstract][Full Text] [Related]
27. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
[TBL] [Abstract][Full Text] [Related]
28. Rational optimization of a HIV-1 Tat inhibitor: rapid progress on combinatorial lead structures.
Klimkait T; Felder ER; Albrecht G; Hamy F
Biotechnol Bioeng; 1998-1999; 61(3):155-68. PubMed ID: 10397803
[TBL] [Abstract][Full Text] [Related]
29. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.
Xiao H; Neuveut C; Tiffany HL; Benkirane M; Rich EA; Murphy PM; Jeang KT
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11466-71. PubMed ID: 11027346
[TBL] [Abstract][Full Text] [Related]
30. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Moncunill G; Armand-Ugón M; Clotet-Codina I; Pauls E; Ballana E; Llano A; Romagnoli B; Vrijbloed JW; Gombert FO; Clotet B; De Marco S; Esté JA
Mol Pharmacol; 2008 Apr; 73(4):1264-73. PubMed ID: 18182480
[TBL] [Abstract][Full Text] [Related]
31. SDF-1-induced activation of ERK enhances HIV-1 expression.
Montes M; Tagieva NE; Heveker N; Nahmias C; Baleux F; Trautmann A
Eur Cytokine Netw; 2000 Sep; 11(3):470-7. PubMed ID: 11022134
[TBL] [Abstract][Full Text] [Related]
32. Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4+ T cells, mediated via cell signaling and Tat cofactor overexpression.
Missé D; Gajardo J; Oblet C; Religa A; Riquet N; Mathieu D; Yssel H; Veas F
AIDS; 2005 Jun; 19(9):897-905. PubMed ID: 15905670
[TBL] [Abstract][Full Text] [Related]
33. Differential effect of tumor necrosis factor-alpha and herpes simplex virus type 1 on the Tat-targeted inhibition of human immunodeficiency virus type 1 replication.
Popik W; Pitha PM
Virology; 1994 Aug; 202(2):521-9. PubMed ID: 8030218
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist.
Hsu MC; Schutt AD; Holly M; Slice LW; Sherman MI; Richman DD; Potash MJ; Volsky DJ
Science; 1991 Dec; 254(5039):1799-802. PubMed ID: 1763331
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
De Clercq E
Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
[TBL] [Abstract][Full Text] [Related]
36. Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101.
Wang X; Yamataka K; Okamoto M; Ikeda S; Baba M
Antivir Chem Chemother; 2007; 18(4):201-11. PubMed ID: 17907378
[TBL] [Abstract][Full Text] [Related]
37. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.
Coburn GA; Cullen BR
J Virol; 2002 Sep; 76(18):9225-31. PubMed ID: 12186906
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans.
Gnabre JN; Brady JN; Clanton DJ; Ito Y; Dittmer J; Bates RB; Huang RC
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11239-43. PubMed ID: 7479972
[TBL] [Abstract][Full Text] [Related]
40. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
Bleul CC; Farzan M; Choe H; Parolin C; Clark-Lewis I; Sodroski J; Springer TA
Nature; 1996 Aug; 382(6594):829-33. PubMed ID: 8752280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
